Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alkylation of guanine bases in DNA is a chemical modification, typically at the O6 position of guanine, resulting from exposure to endogenous or exogenous alkylating agents. This lesion can cause mutagenic mispairing (G:C to A:T mutations) during DNA replication and contributes to carcinogenesis and cytotoxicity. Cells possess direct DNA repair systems—primarily O6-methylguanine-DNA methyltransferase (MGMT)—that remove alkyl groups, thereby reversing the DNA damage. Many anticancer alkylating agents exert their cytotoxic effects by inducing guanine alkylation, while cancer resistance can emerge via increased MGMT activity which counteracts this lesion[1][2][4][5][7][9].
Alkylating agents *cause* DNA alkylation at guanine, resulting in cytotoxic/mutagenic lesions[2][4][5][9]\nDNA repair agents *remove* alkyl groups, reversing alkylation[1][2][3][4][7]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on O6-alkylguanine lesion in DNA.